Faculty Articles

Title

Elvitegravir for the Treatment of HIV

ISBN or ISSN

1744-7666

Publication Title

Expert Opinion on Pharmacotherapy

Volume

17

Issue

17

Publication Date / Copyright Date

10-31-2016

First Page

2359

Last Page

2370

Publisher

Taylor & Francis

DOI Number

10.1080/14656566.2016.1250885

Abstract

Introduction: Current antiretrovirals (ARVs) have demonstrated the ability to prolong the life of an HIV infected individual via suppression of the virus and subsequent restoration of immune function. Despite significant advancement, there remains an opportunity for improvement. One ARV that attempts to fill global HIV therapeutic needs by balancing convenience, safety, and efficacy is elvitegravir (EVG).

Areas covered: Using MEDLINE/PubMed, a literature search was conducted for published articles on the safety and efficacy of EVG in the treatment of HIV infection.

Expert opinion: EVG offers clinicians a convenient choice for HIV-positive patients that is safe and effective for both treatment-naïve and experienced patients, as well as an option for regimen simplification in virologically suppressed patients. EVG is conveniently co-formulated in fixed dose combination tablets to be taken once daily with food. EVG does not require dose adjustment for patients with severe renal impairment or mild to moderate liver disease. Importantly, EVG requires co-administration with a pharmacokinetic enhancer (i.e., ritonavir or cobicistat) in order to achieve therapeutic levels and facilitate once daily dosing. As a consequence, clinicians must carefully review concomitant medications and navigate potential drug-drug interactions mediated through potent inhibition of cytochrome P450 3A enzymes by ritonavir and cobicistat.

Disciplines

Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences

Keywords

AIDS, anti-HIV agents, clinical trials as topic, cobicistat, combination, cytochrome p-450 cyp3a inhibitors, drug interactions, drug therapy, elvitegravir, HIV, HIV-1, HIV infections, humans, integrase inhibitor, integrase strand transfer inhibitor, quinolones, ritonavir, treatment outcome

Peer Reviewed

Find in your library

Share

 
COinS